Difference between revisions of "Talk:Timeline of mRNA research"
From Timelines
(Created page with "== Extended timeline == {| class="sortable wikitable" ! Year !! Condition (when applicable) !! Event type !! Details !! Location |- | 2005 || || Vaccine development || The U...") |
|||
| Line 5: | Line 5: | ||
|- | |- | ||
| 2005 || || Vaccine development || The U.S. Food and Drug Administration (FDA) grants approval for the first mRNA-based vaccine, specifically for rabies in animals. This milestone demonstrates the potential of mRNA technology in vaccine development. The approval marks a significant advancement, showcasing mRNA's ability to generate an immune response by instructing cells to produce proteins that are essential for fighting the virus. This early success paves the way for subsequent development of mRNA vaccines for humans, including those for COVID-19, and highlights the versatility and promise of mRNA technology in combating infectious diseases. || {{w|United States}} | | 2005 || || Vaccine development || The U.S. Food and Drug Administration (FDA) grants approval for the first mRNA-based vaccine, specifically for rabies in animals. This milestone demonstrates the potential of mRNA technology in vaccine development. The approval marks a significant advancement, showcasing mRNA's ability to generate an immune response by instructing cells to produce proteins that are essential for fighting the virus. This early success paves the way for subsequent development of mRNA vaccines for humans, including those for COVID-19, and highlights the versatility and promise of mRNA technology in combating infectious diseases. || {{w|United States}} | ||
| + | |- | ||
| + | | 2018 || Amyloidosis || FDA approval || U.S. {{w|FDA}} approves mRNA-based therapeutics against hereditary ATTR {{w|amyloidosis}}. This condition involves the accumulation of abnormal amyloid proteins in tissues and organs, leading to severe and potentially life-threatening complications. The approval of these mRNA therapeutics represents a significant breakthrough, utilizing mRNA technology to address the genetic root of the disease. By instructing cells to produce proteins that counteract the effects of the amyloid deposits, these treatments aim to slow or halt the progression of the disease, offering new hope for patients affected by this rare and challenging condition.<ref name="The DNA Unive"/> || {{w|United States}} | ||
|- | |- | ||
|} | |} | ||
| + | |||
| + | == References == | ||
Revision as of 21:50, 19 September 2024
Extended timeline
| Year | Condition (when applicable) | Event type | Details | Location |
|---|---|---|---|---|
| 2005 | Vaccine development | The U.S. Food and Drug Administration (FDA) grants approval for the first mRNA-based vaccine, specifically for rabies in animals. This milestone demonstrates the potential of mRNA technology in vaccine development. The approval marks a significant advancement, showcasing mRNA's ability to generate an immune response by instructing cells to produce proteins that are essential for fighting the virus. This early success paves the way for subsequent development of mRNA vaccines for humans, including those for COVID-19, and highlights the versatility and promise of mRNA technology in combating infectious diseases. | United States | |
| 2018 | Amyloidosis | FDA approval | U.S. FDA approves mRNA-based therapeutics against hereditary ATTR amyloidosis. This condition involves the accumulation of abnormal amyloid proteins in tissues and organs, leading to severe and potentially life-threatening complications. The approval of these mRNA therapeutics represents a significant breakthrough, utilizing mRNA technology to address the genetic root of the disease. By instructing cells to produce proteins that counteract the effects of the amyloid deposits, these treatments aim to slow or halt the progression of the disease, offering new hope for patients affected by this rare and challenging condition.[1] | United States |
References
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedThe_DNA_Unive
